Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Trial Profile

GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Itacitinib (Primary) ; Methylprednisolone; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GRAVITAS-309
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 22 Jan 2019 According to an Incyte Corporation media release, results are expected in 2019.
    • 22 Jan 2019 According to an Incyte Corporation media release, first patient has been treated.
    • 12 Sep 2018 Planned End Date changed from 31 Dec 2021 to 17 Oct 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top